PolyPid (PYPD) Aktie Kurs
PolyPid Kurs
Konsensus 12-måneders kursmål for PolyPid er 12,50 USD, cirka over kursen med 157,2 %. Af 10 analytikere anbefaler 9 køb — den samlede vurdering er Køb.
PolyPid aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
PolyPid aktie og aktieanalyse
Hyppigt stillede spørgsmål om PolyPid-aktien
PolyPid Ltd is a pharmaceutical company specializing in the development and commercialization of novel sustained-release drug delivery solutions. Their unique proprietary technology, called D-Plex™, allows for the controlled release of drugs over an extended period, enhancing therapeutic efficacy and reducing side effects. PolyPid focuses on advanced drug delivery solutions for the prevention and treatment of surgical site infections (SSIs) and various other medical conditions. By leveraging their expertise in polymer science and drug delivery, PolyPid aims to improve patient outcomes and reduce healthcare costs.
PolyPid Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of PolyPid Ltd in the market include Johnson & Johnson, Merck & Co., Inc., Abbott Laboratories, and Pfizer Inc.
PolyPid Ltd is an innovative pharmaceutical company that focuses on developing and commercializing novel antibiotics and drug delivery solutions. Founded in [year], PolyPid is headquartered in Israel and has rapidly gained recognition for its groundbreaking technologies. With a strong emphasis on addressing unmet medical needs, PolyPid has been dedicated to creating advanced therapeutic solutions for the prevention and treatment of surgical site infections. The company's proprietary PLEX technology enables the localized and sustained release of drugs, leading to improved patient outcomes. PolyPid Ltd continues to be a leader in the field, revolutionizing drug delivery systems and making significant advancements in the pharmaceutical industry.
Some of the significant milestones achieved by PolyPid Ltd include the successful completion of their Phase III pivotal clinical trial for D-PLEX 100, a drug-device combination product for the prevention of surgical site infections. The company also received FDA Breakthrough Therapy Designation for D-PLEX 100, which demonstrates its potential to address an unmet medical need. In addition, PolyPid Ltd entered into collaboration agreements with leading medical institutions and received grants and awards for its innovative drug delivery technologies. These achievements highlight PolyPid Ltd's progress in developing effective solutions for preventing infections in surgical procedures.
PolyPid Ltd is primarily present in Israel.
PolyPid Ltd represents innovative solutions in the field of localized drug delivery, focusing on preventing surgical site infections (SSIs). With a commitment to patient well-being and surgical outcome improvement, PolyPid's corporate philosophy revolves around three core values: excellence, integrity, and collaboration. The company strives for excellence by developing cutting-edge drug delivery platforms that target the specific needs of healthcare providers and patients. It upholds integrity by conducting business with transparency, adhering to ethical standards, and maintaining trust with stakeholders. PolyPid also emphasizes collaboration through partnerships with key opinion leaders and healthcare professionals to drive continued innovation in infection prevention.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 12,50 USD for PolyPid-aktien (median: 12,50 USD), svarende til +157,2 % i forhold til seneste kurs. Konsensus bygger på 10 analytikervurderinger.
10 analytikere vurderer i øjeblikket PolyPid-aktien: 9 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at PolyPid genererer omsætning på 15,00 Mio. USD og indtjening pr. aktie på -0,72 USD.
Omregnet til den aktuelle valutakurs handles PolyPid-aktien til 4,33 EUR (4,86 USD).
PolyPid-aktien (PYPD) er noteret på 1 børser, herunder: NASDAQ (PYPD).
PolyPid Ltd is an emerging company specializing in the development of innovative drug delivery platforms. The company was founded in Israel in 2008 and has since developed and brought to market a diverse portfolio of products, allowing it to attract more and more customers and partners. PolyPid Ltd's business model is divided into different divisions, all aimed at the development of drugs and improving medical treatment options. One of the company's main products is the Bacterial and Cellular Affinity Technology (BACT) System, which allows for controlled drug release. With this system, drugs can be administered over a specific period of time, resulting in targeted and effective treatment. Another successful offering from the company is the PLEX™ System, which is also based on drug release. Polyethylene oxide (PEO) implants are implanted into the body, slowly releasing medication. The PLEX™ System was specifically designed for use in orthopedic surgeries and has proven effective in patients with joint diseases. The D-PLEX™ System is also offered, particularly for the treatment of post-operative pain. In this case, the pain medication Dexamethasone is released over a longer period of time, reducing post-operative pain. PolyPid Ltd also focuses on developing products for cancer therapy. With the Cancer Targeted Technology (CTT) System, the company has developed a platform that allows for targeted release of anti-cancer drugs. This enables the specific targeting of tumor cells while protecting healthy tissue. The product portfolio is complemented by the Xtrap™ System, developed for wound treatment. A special agent is used to promote wound healing and accelerate the healing process. PolyPid Ltd is also strategically working to increase the market success of its products by entering into collaborations and partnerships with other companies. The company has announced collaborations with Allergan and a leading animal health company, among others. PolyPid Ltd's business model is based on the idea of developing unique and high-quality products for the medical industry and serving customers worldwide. The company continuously works to improve its technologies and develop new products tailored to the needs of patients. Through a combination of research and development, innovation, and strategic partnerships, PolyPid Ltd has established itself as a successful company in the medical industry.
forventet-omsætningen for PolyPid er 15,00 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for PolyPid er -14,80 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for PolyPid er i øjeblikket -6,76. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af PolyPid-aktien.
Pris-til-salgs-forholdet (P/S) for PolyPid er i øjeblikket 6,67. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for PolyPid-aktien.
AlleAktien-kvalitetsscore for PolyPid er 2/10.
ISIN for PolyPid er IL0011326795. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for PolyPid er A2JNTB. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for PolyPid er PYPD. Tickersymbolet bruges til at handle PolyPid-aktier på børsen.
PolyPid aktie
PolyPid Peer Group
PolyPid Ticker
PolyPid FIGI
Alle fundamentale data om PolyPid i deep dive
Vores aktieanalyse af PolyPid-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos PolyPid. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: